Drug Designing: Open Access
Open Access

Azhar Mehmood

Publications

• Research Article
  Repurposing of Modified Alpidem and Propoxyphene to Cure AURKA, BCAS1, GNAS and MLH1 Gene Mutations in Colorectal Cancer
  Author(s): Anum Munir, Shumaila Azam, Sartaj Ali, Azhar Mehmood, Abbas Hussain Shah, M Saad Khan, Rabbiah Manzoor, Maria Sana, Shakeel Ahmed Mufti and Sahar FazalAnum Munir, Shumaila Azam, Sartaj Ali, Azhar Mehmood, Abbas Hussain Shah, M Saad Khan, Rabbiah Manzoor, Maria Sana, Shakeel Ahmed Mufti and Sahar Fazal
  
  Background: Colorectal cancer is a varied illness with an expected heritability of 25–30%. Many CRC disorders occur because of solid family history, a high penetrance of the infection, and developing various tumors at an early age. A few novel genes are recognized that shows associations with CRC, such as AURKA, BCAS1, GNAS and MLH1. Material and methods: In this research work FDA rejected Alpidem and Propoxyphene were selected. Drugs were changed on the basis of side effects; modified drugs were docked with AURKA, BCAS1, GNAS and MLH1 proteins and QSAR analysis was performed. Results: Docked and QSAR results demonstrated the better interaction of both modified Alpidem and Propoxyphene along with proteins of CRC causing genes. The toxicity value and side-effects of modified Alpidem and modified Propoxyphene are l.. View More»
  DOI: 10.4172/2169-0138.1000141

  Abstract PDF

Relevant Topics